245 related articles for article (PubMed ID: 33469997)
1. Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF
Li L; Li H; Zhang J; Gao X; Jin H; Liu R; Zhang Z; Zhang X; Wang X; Qu P; Zhao Y; Lu X
J Cell Mol Med; 2021 Feb; 25(3):1739-1749. PubMed ID: 33469997
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
4. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
5. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
[TBL] [Abstract][Full Text] [Related]
6. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
Xu X; Ma X; Zhang X; Cao G; Tang Y; Deng X; Kang Z; Li M; Guan M
Clin Chim Acta; 2019 Apr; 491():91-96. PubMed ID: 30682328
[TBL] [Abstract][Full Text] [Related]
7. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
8. BRAF
Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T
Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980
[No Abstract] [Full Text] [Related]
9. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
10. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.
Puli OR; Danysh BP; McBeath E; Sinha DK; Hoang NM; Powell RT; Danysh HE; Cabanillas ME; Cote GJ; Hofmann MC
Neoplasia; 2018 Nov; 20(11):1121-1134. PubMed ID: 30265861
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
12. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
15. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
19. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
Liu Z; Lv T; Xie C; Di Z
Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
